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BACKGROUND: Less than 20% of lifetime smokers will ever develop cancer. Smoking habits characteristics, particularly
the level of nicotine dependence level, were not fully evaluated as a marker of risk.
METHODS: Case–control study of voluntary patients prospectively enrolled in a smoking cessation program in a cancer
hospital. For each cancer case, patients of the same age and sex were selected. The Beck Depression Inventory, an instrument
for the diagnosis of depressive mood and clinical depression, and the Fagerström Test Questionnaire, a questionnaire that
has a good correlation with nicotine levels, used to determine the degree of dependence on nicotine, were applied. Age on
admission to the study, sex, and number of pack-years were also evaluated.
RESULTS: From May 1999 to May 2002, 56 cancer patients (case) and 85 matching controls (control) were identified in the
population studied. There was no difference regarding pack-years. Fagerström Test Questionnaire was significantly higher
in patients with cancer (7.5 ± 1.9) compared to controls (6.3 ± 2.0). We found a Fagerström Test Questionnaire ≥ 7 in 73.2%
of the cancer cases versus 43.5% of the controls (p=0.001). The proportion of depressed patients was higher in the cancer
group (37.5% x 17.6%). Logistic regression adjusted for age and tobacco consumption disclosed that Fagerström Test
Questionnaire score ≥ 7 has an odds ratio for cancer of 3.45 (95% CI 1.52 – 7.83, p = 0.003).
CONCLUSION: Fagerström Test Questionnaire higher than 7 was identified as a risk factor for cancer in smokers with
similar tobacco consumption.
KEYWORDS: Smoking cessation. Fagerström Test. Cancer. Tobacco.
Although the role of tobacco smoking as a causative
agent for a great number of cancer types is established1-5,
less than 20% of lifetime smokers will ever develop can-
cer6. Genetic polymorphism may explain cancer risk
through the effects on carcinogen metabolism and detoxi-
fication on steps of cellular metabolism, on smoking
behavior and nicotine addiction 7. A possible marker of risk,
the nicotine dependence level, has not been fully evalu-
ated in cancer patients before.
Higher nicotine dependence, pointed out by a
Fagerströn Tolerance Questionnaire (FTQ) ≥ 7, was recently
described as a prognosticator of failure in tobacco cessa-
tion programs8. Regarding the incidence of chronic obstruc-
tive pulmonary disease (COPD), a clear difference in the
level of nicotine dependence and presence of disease in
smokers was recently described9. Moreover 30% of smok-
ers with COPD, presented a FTQ greater than seven points,
a proportion significantly higher that the found in healthier
smokers9.
The Fagerstrom Tolerance Questionnaire has been
shown to correlate well with tobacco consumption in can-
cer patients10, as well as in non-cancer patients11. As such,
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the aim of the present study was to assess whether there is
a difference in smoking habits, particularly the levels of de-
pendence between smokers with cancer and those without.
METHODS
Patients were retrospectively identified from those pro-
spectively enrolled in the Smokers’ Support Group at the
Hospital do Cancer A.C. Camargo in São Paulo, Brazil. Out-
patient smokers enrolled in the group spontaneously.
At the initial interview with a psychiatrist, the Beck De-
pression Inventory (BDI), an instrument validated for the
diagnosis of depressive mood and clinical depression, and
the Fagerström Test Questionnaire (FTQ), a questionnaire
that has a good correlation with nicotine levels, were ap-
plied. The BDI includes 21 questions that screen for depres-
sion symptoms. The FTQ comprises smoking habit related
questions such as “how long do you take before smoking
the first cigarette after awakening?”, “which is the worst
cigarette to quit?”, or “do you smoke when sick?”. The
questionnaire was used to determine the degree of depend-
ence on nicotine. Following the first visit, subgroups of 15
patients were formed and these subgroups returned weekly
for behavioral orientation related to smoking cessation8.
Inclusion criteria were age, ranging from 18 to 65 years,
and a minimum smoking habit of 15 cigarettes/day in the
last year. Cancer patients were identified in the first clinical
visit based on their history. Confirmation of the diagnosis of
malignancy was obtained from the medical records. A con-
trol group was matched by sex and age, tolerating an up to
two year age difference for each case. Cancer was excluded
in the subjects of this group based on a thorough medical
history, a complete physical examination and a chest x-ray.
As the clinical status was obtained based on the interview,
the only exclusion criterion was patients having any signs
of mental impairment or demential syndromes.
Statistical analysis
Variables determined at the first interview (Beck score,
Fagerström test score, age on admission to the study, sex,
number of years smoked and cigarettes per day smoked in
the last year and finally the number of pack-years someked
obtained by the product of the last two variables) were
evaluated. Student-T test was used for normal continuous
variables, Mann – Whitney test for non normally distrib-
uted variables and the Chi-square test for categorical vari-
ables. To determine the odds ratio of each variable in rela-
tion to cancer, logistic regression was utilized using the enter
procedure. For that analysis, depression was established as
a Beck score equal to 20 or greater. Fagerstrom was divided
into two categories; lower or equal and greater than 7, as
we have recently shown that such categories are directly
related to difficulties to quit8. The level of significance was
established at 5%. Statistical analyses were performed us-
ing the SPSS for Windows (8.0).
RESULTS
From May 1999 to May 2002, 56 cancer patients were
identified at the Smokers´ Support Group (CASE). Final di-
agnosis of these cases are described in table1. Eighty-five
matching controls were identified in the population stud-
ied (CONTROL). The total group completing the study was
predominantly female, 64.5%. The age varied between 35
and 70 years with a mean of 51.9 ± 8.7 years (mean±SD).
The Fagerström Test Questionnaire mean was 6.8 ± 2.0, with
55.3% of the entire population presenting a score ≥ 7. Mean
Beck Depression Inventory score was 15.6 ± 8.6 with 25.5%
of the study group scoring as depressed. The whole group
smoked 23.8 ± 11.1 cigarettes per day with a smoking his-
tory of 34.6 ± 9.5 years.
As expected, we found no significant differences be-
tween the two populations regarding sex and age. Neither
was there any difference regarding the number of pack-years
smoked.
FTQ was significantly higher in patients with cancer
compared to controls. We found a FTQ ≥ 7 in 73.2% of the
cancer cases versus 43.5% of the controls (p=0.001). BDI
was also significantly higher in the cancer group, as com-
pared to the controls. The proportion of depressed patients
was higher in the cancer group (37.5% x 17.6%). Univariate
analyses for each variable is described in table 2.
Table 1 - Histology and primary organ affected in the cancer
patients.
Histology Primary Organ n % of total
Epidermoid Carcinoma Tonsil 4 7.0
Larynx 7 12.5
Mouth 5 9.0
Lung 5 9.0
Ocular 1 1.8
Supra Glotis 1 1.8
Unknown 1 1.8
Adenocarcinoma Lung 3 5.2
Ovary 4 7.0
Thyroid 2 3.6
Oat Cell Carcinoma Lung 4 7.0
Carcinoma Bladder 5 9.0
Cervix Uteri 1 1.8
Breast 1 3 23.0
Multiple Melanoma 2 3.6
Sarcoma Lung 1 1.8
Total 56 100.0
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Logistic regression adjusted for age and tobacco con-
sumption disclosed that FTQ score ≥ 7 has an odds ratio
for cancer of 3.45 (95% CI 1.52 – 7.83, p = 0.003) and de-
pression has an odds ratio of 2,95 (95% CI 1.27-6.85, p =
0.012). There was no significant association between both
variables (p = 0.444, Chi-square).
DISCUSSION
Comparing cancer patients enrolled spontaneously in a
smoking cessation group with those without cancer, only
the level of nicotine dependence, assessed by the FTQ, and
depression, as assessed by the BDI score, were significantly
different. An FTQ higher than 7 was clearly identified as a
risk factor for cancer in smokers with similar tobacco con-
sumption.
The increased number of depressed patients in the can-
cer population was not unexpected. Patients dealing with
cancer present a higher Beck Depression Inventory score
than patients with other diseases12. The prevalence of de-
pression in patients with cancer ranges from 1% to 53%,
depending mostly on the methodology and diagnostic cri-
teria utilized13. As such, our finding of 37.5% of depressed
patients depicted by the Beck Depression Inventory, is in
accordance with previous data. Interestingly, we found no
correlation between depression and nicotine dependence in
our study population. Association between the two traits
has been described, either with depression increasing the
likelihood of nicotine dependence over time as well as high
nicotine dependence being associated with a higher rate of
first incidence major depression14. Since our study did not
address temporal effects, this may explain the lack of asso-
ciation we found.
In our view, the most significant finding of our study
was a higher level of nicotine dependence in patients with
cancer. One possible explanation is that patients who con-
tinue to smoke after a cancer diagnosis are highly depend-
ent. However, considering the first cigarette after awaken-
ing , more than 75% of newly diagnosed cancer patients
enrolled in a cessation trial can be classified as highly de-
pendent15. It is known that, even considering lifetime burn-
ing up, only some 20% of smokers will ever develop can-
cer6. Therefore, the finding of specific risk factors would
permit a more focused intervention toward smoking cessa-
tion. The clearly established association of cancer and quan-
tities of smoked tobacco1-5, involves an a posteriori risk fac-
tor. In other words, a person would be at risk after having
smoked a certain amount of tobacco. The finding that pa-
tients with cancer scored higher nicotine dependence indi-
cates a risk factor that can be established a priori. The reli-
ability of FTQ has been already acknowledged16, however
its variation over time for the same subject to our knowl-
edge has not been studied so far.
A good correlation between FTQ scores and serum lev-
els of tobacco products is well established17-18. As such, the
FTQ may be more related to tobacco exposure than the re-
called amount of smoked cigarettes, which is subject to a
recall bias19 and therefore, be a more reliable indicator of
risk exposure.
Interestingly, lower nicotine dependence (Fagerstrom
score < 6) is associated with a 4 fold odds of long term ab-
stinence in smoking cessation with nicotine patch20 and a
lower FTQ also predicts higher abstinence from smoking
while using Bupropion21. Moreover, it was recently reported
that nicotine dependence defined by the Fagerstrom test for
nicotine dependence (FTQ) predicted one year abstinence
better than the Diagnostic and Statistic Manual of Mental
Disorders (DSM) definition, suggesting that different as-
pects of nicotine dependence are captured by the different
approaches 22. The above comments are particularly impor-
tant since a clear demonstration of decreased risk of lung
cancer with smoking cessation even at middle age was re-
Table 2 - Univariate analysis of demographics, tobacco consumption, Fagerströn Tolerance Questionnaire and Beck
Depression Inventory between cancer patients and matched controls.
Cancer Patients Controls P
N = 54 N =85
Sex 32 F: 24M 59 F: 26 M 0.14 *
Age (y) 52.9 ± 8.7 51.3 ± 8.7 0.31 #
Cigarettes per day 25.5 ± 13.2 22.6 ± 9.4 0.13 #
Smoking Years 34.9 ± 10.6 34.4 ± 8.7 0.71 #
Pack -Years 43.8 ± 24.2 38.7 ± 17.2. p = 0.17
Fagerström Test 7.5 ± 1.9 6.3 ± 2.0 <0.001 #
Fagerström ³ 7 (%) 73.2% 43.5% 0.001 *
Beck Depression 17.7 ± 8.9 14.3 ± 8.2 0.022 #
Inventory
BDI > 20 37.5% 17.6% 0.01 *
* Chisquare, # Students t Test
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cently described 3. Although a 3.5 odds ratio for cancer in
smokers with a Fagerstrom Score ³ 7 was found in the
present study, it is noteworthy that in a population of 157
lung and head neck cancer patients, hence strongly related
to tobacco consumption, a group with low Fargestrom score
was found, suggesting that nicotine dependence is not the
only risk factor 10.
In summary , nicotine dependence, as measured by the
FTQ, seems to be a risk factor for cancer in smokers. Such
results need to be confirmed in prospective studies that in-
clude not only other risk factors, but also address
populations with a single type of cancer.
RESUMO
Deheinzelin D, Lourenço MTC, Costa CL da, Younes RN.
O nível de dependência da nicotina é um fator de risco
independente para o câncer. Um estudo caso-controle.
Clinics. 2005;60(3):221-26.
OBJETIVO: Menos de 20% dos fumantes crônicos
desenvolverá cancer. As características do hábito de fumar,
particularmente o nível de dependência à nicotina, não
foram avaliadas inteiramente como um marcador do risco.
MÉTODOS: Estudo caso-controle de pacientes voluntários,
registrados prospectivamente em um programa de cessação
de tabagismo em um hospital de cancer. Para cada caso de
cancer, pacientes da mesma idade e sexo foram selecionados.
O inventário de depressão de Beck, um instrumento
validado para diagnóstico de estado depressivo e depressão
clínica e o questionário de tolerância de Fagerstron , que é
usado para determinar o grau de dependência e tem boa
correlação com níveis de nicotina, foram aplicados. Idade
na admissão ao estudo, sexo, número de maços-anos
fumados foram avaliados também.
RESULTADOS: De maio de 1999 a maio de 2002, 56
pacientes de câncer (caso) e 85 controles pareados (controle)
foram identificados na população estudada . Não houve
diferença quanto ao número de maços-ano. O questionário
de tolerância de Fagerstron foi significativamente mais
elevado nos pacientes com câncer (7.5 ± 1.9) comparado
aos controles (6.3 ± 2.0). Encontramos um questionário de
tolerância de Fagerstron > 7 em 73.2% dos casos de câncer,
contra 43.5% dos controles (p=0.001). A proporção de
pacientes deprimidos foi mais elevada no grupo do cancer
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